我要投票 半边天NEWOMEN在乌鸡白凤丸行业中的票数:138
· 外 推 电 报 ·
2025-02-05 17:45:44 星期三

【半边天NEWOMEN是哪个国家的品牌?】

半边天NEWOMEN是什么牌子?「半边天NEWOMEN」是 江西半边天药业有限公司 旗下著名品牌。该品牌发源于香港,由创始人翁汉辉在1998-04-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

始于1998年,香港半边天药业国际集团旗下,专注妇科中成药、保健品的研发、生产、销售的制药公司


半边天药业国际集团(香港)有限公司成立于一九九八年四月,目前拥有江西半边天药业有限公司、深圳市半边天保健品有限公司、深圳市金药坊医药有限公司等多家下属企业,并在江西省泰和经济开发区建有占地十六万余平方米的生产基地——半边天药业国际集团工业城,固定资产规模达人民币2亿多元,其国内总部设在深圳。

半边天药业国际集团本着“专心造好药,健康半边天”的经营宗旨,专注妇科中成药、保健品的研发、生产、销售,已形成具有调经类、乳腺类、补血类、消炎类、排毒类等多种功能的妇科产品线,主要品种有国家中药保护品种和新药复方乌鸡口服液、乳宁丸、阿胶益寿口服液、乌鸡白凤丸、芦荟胶囊、妇舒洁洗液、妇炎康片等。

半边天药业国际集团下属的成员企业江西半边天药业拥有:口服液、糖浆、蜜丸、水丸、洗液等多条具有国内专业水平的生产线;生产能力10亿元以上;2004年和2009年两次通过国家药监局的GMP认证。目前正在建设中的二期工程包括了片剂、胶囊剂、颗粒剂等多种剂型。二期工程预计2012年完工建成。

半边天药业国际集团坚持以市场为导向,下属成员企业深圳金药坊医药有限公司是集团公司的营销中心,已于二OO四年六月顺利通过GSP认证,目前已建成以深圳为中心,辐射华南、华东、中南、西南的销售网络,在广东、广西、云南、贵州、湖南、湖北、重庆、四川、江苏、江西、安徽、浙江、山东等二十多个省、直辖市、自治区设立了二百多个营销分支机构,建立了一千多人的专业销售队伍。

半边天药业国际集团注重科技创新,与国内外多家医药研究机构建立了密切合作关系,实现了产品研发、信息交流、市场开拓、人才培养友好互动,生产、储备、研制、构想齐头并进的良好发展格局。

未来,半边天药业国际集团将继续“专业妇科品牌”的道路,通过并购、合作等多种途径,丰富产品群,扩大销售规模,进一步提升品牌影响力,积极寻求上市,实现中国医药市场妇科品牌的战略目标。


英文翻译:Started in 1998, half sky Pharmaceutical International Group (Hong Kong) Co., Ltd., a pharmaceutical company under half sky Pharmaceutical International Group in Hong Kong, which focuses on the research and development, production and sales of Chinese medicine for gynecology and health care products, was founded in April 1998. At present, it has Jiangxi half sky Pharmaceutical Co., Ltd., Shenzhen half sky health care products Co., Ltd., Shenzhen Golden Pharmaceutical Co., Ltd., etc There are more than 160000 square meters of production base - banbiantian Pharmaceutical International Group Industrial City in Taihe Economic Development Zone of Jiangxi Province, with fixed assets of more than 200 million yuan. Its domestic headquarters is located in Shenzhen. Based on the business tenet of "concentrate on making medicine, healthy half sky", banbiantian Pharmaceutical International Group focuses on the R & D, production and sales of Chinese traditional medicine and health care products in gynecology. It has formed a gynecology product line with multiple functions such as menstrual regulation, breast, blood tonic, anti-inflammatory, detoxification, etc. the main varieties are national traditional Chinese medicine protection varieties and new compound Wuji oral liquid, runing pill, a Jiaoyishou oral liquid, Wuji Baifeng pill, aloe capsule, fushujie lotion, Fuyankang tablet, etc. Jiangxi banbiantian Pharmaceutical Co., Ltd., a member enterprise of banbiantian Pharmaceutical International Group, has many production lines with domestic professional level, such as oral liquid, syrup, honey pill, water pill, lotion, etc.; the production capacity is more than 1 billion yuan; in 2004 and 2009, it passed the GMP certification of the State Food and Drug Administration twice. At present, the second phase project under construction includes tablet, capsule, granule and other dosage forms. The second phase of the project is expected to be completed in 2012. Banbiantian Pharmaceutical International Group adheres to the market orientation, and its subordinate member company Shenzhen jinyaofang Pharmaceutical Co., Ltd. is the marketing center of the group company. It has successfully passed the GSP certification in June 2004. At present, it has established a sales network with Shenzhen as the center, radiating South China, East China, Central South China and southwest China. It is located in Guangdong, Guangxi, Yunnan, Guizhou, Hunan, Hubei, Chongqing and Siyuan Sichuan, Jiangsu, Jiangxi, Anhui, Zhejiang, Shandong and more than 20 provinces, municipalities and autonomous regions have set up more than 200 marketing branches and established a professional sales team of more than 1000 people. Banbiantian Pharmaceutical International Group attaches great importance to scientific and technological innovation, and has established close cooperation with a number of pharmaceutical research institutions at home and abroad. It has achieved a good development pattern of product research and development, information exchange, market development, friendly interaction of talent training, and simultaneous development of production, reserves, research and ideas. In the future, banbiantian Pharmaceutical International Group will continue to be a "professional gynecological brand", enrich the product group, expand the sales scale, further enhance the brand influence, actively seek listing, and achieve the strategic goal of gynecological brand in China's pharmaceutical market through M & A, cooperation and other ways.

本文链接: https://www.waitui.com/brand/fae4e258c.html 联系电话:07965376611

千城特选小程序码

7×24h 快讯

九洲药业:子公司浙江瑞博通过美国FDA现场检查

36氪获悉,九洲药业公告,公司子公司浙江瑞博制药有限公司于2024年10月28日至2024年11月1日期间接受了美国食品药品监督管理局的cGMP现场检查,检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日,浙江瑞博收到美国FDA签发的现场检查报告(EIR,Establishment Inspection Report),该报告表明浙江瑞博已通过本次cGMP现场检查。检查范围为浙江瑞博涉及产品(非无菌原料药卡马西平、文拉法辛苯磺酸盐 —水合物以及药物中间体沙库巴曲)的生产制造。

2小时前

美图:公司旗下产品采用了DeepSeek技术

36氪获悉,据摩根士丹利透露,美图公司旗下的美图设计室已采用DeepSeek技术,主要为AI生成PPT相关功能。

2小时前

硅业分会:多晶硅企业年后集中签单在即,硅料环节持续去库

36氪获悉,据中国有色金属工业协会硅业分会消息,本周逢春节假期,多晶硅企业整体暂无规模性签单,多晶硅市场价格维持稳定。n型复投料成交价格区间为3.90-4.50万元/吨,成交均价为4.17万元/吨,n型颗粒硅成交价格区间为3.80-4.10万元/吨,成交均价为3.90万元/吨,p型多晶硅成交价区间为3.20-3.60万元/吨,成交均价为3.40万元/吨。本周多晶硅企业正常执行前期订单,年后订单仍在洽谈中。目前下游硅片企业排产有上调预期,对多晶硅需求量稳步增长。

2小时前

传宁德时代考虑提交香港上市申请,官方暂无回应

今日有消息称,宁德时代据称考虑在未来几周提交香港上市申请。针对此事,宁德时代方面暂无回应。此前,2024年底也有外媒报道称,宁德时代考虑最快于2025年在香港上市,筹集至少50亿美元。(新浪科技)

2小时前

华泰股份:股票连续12个月收盘价均低于每股净资产,公司制定估值提升计划

36氪获悉,华泰股份公告,公司股票连续12个月每个交易日收盘价均低于最近一个会计年度经审计的每股归属于公司普通股股东的净资产,根据《上市公司监管指引第10号——市值管理》的相关规定,华泰股份制定估值提升计划。公司估值提升计划已经公司第十一届董事会第四次会议审议通过。华泰股份估值提升计划将围绕生产经营、现金分红、股份回购、股东增持、投资者关系管理以及信息披露等方面。

2小时前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询